A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Seagen Inc.
Arcus Biosciences, Inc.
Qurient Co., Ltd.
AbbVie
AstraZeneca
ImmunityBio, Inc.
HiFiBiO Therapeutics
Akeso
TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
Merck Sharp & Dohme LLC
Jiangsu HengRui Medicine Co., Ltd.
Adcentrx Therapeutics
Klus Pharma Inc.
Tempus AI
Agenus Inc.
Xencor, Inc.
Taiho Oncology, Inc.
NextCure, Inc.
Merck Sharp & Dohme LLC
NGM Biopharmaceuticals, Inc
NETRIS Pharma
NGM Biopharmaceuticals, Inc
Cornerstone Robotics
Adlai Nortye Biopharma Co., Ltd.
NGM Biopharmaceuticals, Inc
Beijing Health Guard Biotechnology, Inc